Table 1 Description of doses administered and case reports following COVID-19 vaccines
From: A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study
Characteristics | N (%) |
|---|---|
Administered doses | 5,134,093 |
 Vaccine type | |
  Pfizer-BioNTech | 4,259,387 (82.96) |
  AstraZeneca | 717,370 (13.97) |
  Sputnik V | 123,520 (2.41) |
  Sinopharm | 17,934 (0.35) |
Case reports | 6808 |
 Seriousness criteria | |
  Serious case reports | 452 (6.64) |
  Non-serious case reports | 6356 (93.36) |
 Non-serious case reports by vaccine type | |
  Pfizer-BioNTech | 3955 (62.20) |
  AstraZeneca | 2164 (34.10) |
  Sputnik V | 225 (3.50) |
  Sinopharm | 12 (0.20) |
 Gender | |
  Female | 4135 (60.7) |
  Male | 2673 (39.3) |
 Age | |
  12–17 | 248 (3.67) |
  18–44 | 3741 (55.33) |
  45–64 | 1999 (29.57) |
  65–74 | 350 (5.18) |
  > 75 | 423 (6.25) |
 Onset of AEFIs | |
  After dose 1 | 5231 (76.9) |
  After dose 2 | 1369 (20.12) |
  After dose 3 | 202 (2.98) |
 Governorates | 6642 (100) |
  Mount Lebanona | 2845 (42.83) |
  Beirutb | 2015 (30.34) |
  North Lebanonc | 852 (12.83) |
  South Lebanond | 597 (9.0) |
  Bekaa/Baalbeck-Hermele | 333 (5.0) |
 Means of reporting | |
  IMPACT platform | 3829 (56.3) |
  1214 Hotline Call Center | 1979 (29.0) |
  Vaccination centers | 924 (13.6) |
  Others | 76 (1.1) |